Taken together, the disintegration of the NO-cGMP pathway represents a critical determinant of blood pressure development in DOCA-salt hypertension and NDP-α-MSH treatment may provide additional benefits in the management of hypertension through its positive impact on the eNOS system and NO-mediated vascular responses. The gene discussed is STAMBP; the disease is Hypertension.